Evidence map›Paper›PMID 42621159›Full record

ArticleiScience2026

Emergence of neutralizing RBD antibodies following Omicron infection with limited activity against ancestral SARS-CoV-2.

Michael S Piepenbrink, Yao Ma, Simran Panjwani, Alexandra R Blake, Allison M Bell, James L Kizziah, Sara H Mahmoud, Gregory C Ippolito, Nathan B Erdmann, Paul A Goepfert and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michael S PiepenbrinkHeersink School of Medicine, Infectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Yao MaDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Simran PanjwaniHeersink School of Medicine, Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Alexandra R BlakeHeersink School of Medicine, Infectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Allison M BellHeersink School of Medicine, Infectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
James L KizziahHeersink School of Medicine, Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Sara H MahmoudDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Gregory C IppolitoDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Nathan B ErdmannHeersink School of Medicine, Infectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Paul A GoepfertHeersink School of Medicine, Infectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Luis Martinez-SobridoDepartment of Disease Intervention and Prevention, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
James J KobieHeersink School of Medicine, Infectious Diseases Division, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Mark R WalterHeersink School of Medicine, Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
Acquisition of cryo-electron microscopeS10OD024978 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DOKLAND, TERJE · 2020 to 2020
$2.0M
NCI NIH HHS P30 CA013148NIAID NIH HHS R01 AI161175NIH HHS S10 OD024978
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution reduces the efficacy of prophylactic vaccines and monoclonal antibody (mAb) therapies. To evaluate potency and breadth, receptor binding domain (RBD)-targeting neutralizing mAbs were identified from patient B cells using an Omicron KP3.1.1 Spike (S) protein bait. MAbs exhibiting the greatest neutralization potency (1332D4 and 1332E5) and binding breadth (1324A10 and 1316C10) were evaluated in greater detail. Cryo-electron microscopy (Cryo-EM) studies revealed 1332D4 and 1332E5 target RBD residue segments 439-446 and 498-506 of KP3.1.1 S, respectively. 1332E5 is a knob

Indexed as

broadly neutralizing antibodycryoEMKP3.1.1OmicronSARS-CoV-2structurevariant

Identifiers

PMID42621159
PMCPMC13486884

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.